Naloxone prefilled syringe - Emergent BioSolutions
Alternative Names: AP 004Latest Information Update: 02 Oct 2021
At a glance
- Originator Adapt Pharma; Emergent BioSolutions
- Developer Adapt Pharma
- Class Antidotes; Behavioural disorder therapies; Benzofurans; Drug withdrawal therapies; Isoquinolines; Ketones; Laxatives; Morphinans; Small molecules
- Mechanism of Action Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Opioid-related disorders
Most Recent Events
- 16 Jun 2021 Discontinued - Clinical-Phase-Unknown for Opioid-related disorders in Ireland (Parenteral) (Emergent Biosolutions pipeline, June 2021)
- 27 Apr 2020 Emergent BioSolutions announces intention launch naloxone prefilled syringe in the second half of 2020
- 15 Oct 2018 Adapt Pharma has been acquired by Emergent BioSolutions